Summary:
The CLEAR Program includes four randomized, double-blind, placebo-controlled studies to assess the effects of bempedoic acid on endpoints related to cardiovascular disease and its associated risks. Approximately 15,000 patients from across the world will take part.
The CLEAR Outcomes Study will assess the effect of bempedoic acid on the risk of major adverse cardiovascular events in patients with, or at high risk for, cardiovascular disease who are statin intolerant.
The CLEAR Serenity Study will determine whether bempedoic acid can help to lower LDL-C levels in patients with elevated LDL-C levels who are statin intolerant
The CLEAR Wisdom Study will assess the efficacy of bempedoic acid for lowering LDL-C levels in patients with high cardiovascular risk with hyperlipidemia (with underlying heterozygous familial hypercholesterolemia and/or atherosclerotic cardiovascular diseases)
The CLEAR Tranquility Study will evaluate bempedoic acid as an add-on to ezetimibe therapy in patients with elevated LDL-C
Qualified Participants Must:
• Be older than 18 years of age
•
Patient-reported statin intolerance, defined as an inability to tolerate two or more statins, one at a low dose
•
Have a current history of low-density lipoprotein cholesterol (LDL-C) values of between 100 mg/dL and 190 mg/dL despite stable optimized background lowering therapy
Qualified Participants May Receive:
Compensation for time and travel